Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/16/2017 11/17/2017 11/20/2017 11/21/2017 11/22/2017 Date
170.77(c) 170(c) 168.79(c) 169.84(c) 169.96(c) Last
3 131 040 2 039 739 2 012 777 2 629 620 1 533 133 Volume
+0.82% -0.45% -0.71% +0.62% +0.07% Change
More quotes
Financials ($)
Sales 2017 22 886 M
EBIT 2017 11 755 M
Net income 2017 8 326 M
Finance 2017 6 819 M
Yield 2017 2,65%
Sales 2018 22 904 M
EBIT 2018 11 746 M
Net income 2018 8 311 M
Finance 2018 11 102 M
Yield 2018 2,87%
P/E ratio 2017 15,10
P/E ratio 2018 15,04
EV / Sales2017 5,09x
EV / Sales2018 4,90x
Capitalization 123 B
More Financials
Company
Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses.The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.Its products include... 
Sector
Pharmaceuticals
Calendar
12/09 | 11:30amPresentation
More about the company
Surperformance© ratings of Amgen
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN
11/21 Shire appoints Thomas Dittrich as CFO
11/17 AMGEN : First Avastin biosimilar candidate recommended for European approval
11/17 AMGEN : Launches The ENBREL Mini™ Single-Dose Prefilled Cartridge With Aut..
11/17 AMGEN : Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTo..
11/17 AMGEN : New Analyses Presented At AHA 2017 Show Repatha Significantly Reduced Ca..
11/16 AMGEN : Patent Application Titled "Methods of Treating Graft versus Host Disease..
11/16 DATA FROM AMGEN ADVANCE KNOWLEDGE IN : leaping forward with CRISPR)
11/16 AMGEN : ex-dividend day
11/14 AMGEN : Operations Team Honored with Environmental Sustainability Achievement
11/14 AMGEN : EU regulators back Avastin biosimilar
More news
Sector news : Pharmaceuticals - NEC
02:49aDJGLAXOSMITHKLINE : Files Additional Trelegy Ellipta Application to FDA
11/22 BAYER : Brazil pushes back decision on Bayer-Monsanto tie-up
11/22 European shares retreat on euro bounce; UK flat after budget
11/22 FTSE gets sterling boost, land purchase threat dents housebuilders
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on AMGEN 
AMGEN - 11/10
Back on key levels based on weekly price data
BUY
AMGEN, INC. - 2016
Expectation of a turn-around
BUY
More Strategies
News from SeekingAlpha
11/22 Cabozantinib Franchise Will Continue To Transform Exelixis' Fortunes In 2018
11/22 Mystery Stocks Revealed In My 88 Stock Portfolio Along With 2018 Income Estim..
11/19 Victory Formation Long/Short Portfolio Update - November 2017
11/17 Amgen launches Enbrel in single-dose cartridge format for autoinjector
11/15 YOUR DAILY PHARMA SCOOP : Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA A..
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 190 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN16.16%123 376
JOHNSON & JOHNSON19.78%371 653
NOVARTIS11.20%220 090
ROCHE HOLDING LTD.-1.55%212 522
PFIZER8.90%211 844
MERCK AND COMPANY-6.23%148 014